Abstract Title:

Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study.

Abstract Source:

Cancer Invest. 2010 May 18. Epub 2010 May 18. PMID: 20482249

Abstract Author(s):

Michele Orditura, Gennaro Galizia, Vincenzo Napolitano, Erika Martinelli, Roberto Pacelli, Eva Lieto, Gaetano Aurilio, Loredana Vecchione, Floriana Morgillo, Giuseppe Catalano, Fortunato Ciardiello, Alberto Del Genio, Natale Di Martino, Ferdinando De Vita

Article Affiliation:

Division of Medical Oncology,1 Division of Surgical Oncology, Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, School of Medicine, Naples, Italy,2 Division of Radiotherapy, Federico II University of Naples, School of Medicine, Naples, Italy3.

Abstract:

ABSTRACT We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction>50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.

Study Type : Human Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.